Dulaglutide is a new long-acting GLP-1R agonist. It is obtained by fusion of two GLP-1 analogues with DPP-4 inhibitory effect and human immunoglobulin heavy chain IgG4-Fc fragment. Its activity is comparable to that in clinical manifestations. Endogenous GLP-1 is similar, with a half-life of 5 days, which can effectively delay the clearance of the kidneys. The FDA approved the marketing of dulaglutide subcutaneous injection in September 2014. The European Commission approved dulaglutide subcutaneous injection in Europe in December 2014.
Storage:Cool dry place( Store at -20°C, away from the light)
Remark:For Research Use Only. Not for human use.
China